CGTX: Cognition Therapeutics Inc insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
66 institutions reported holding $25.88M of Cognition Therapeutics Inc on Form 13F (75 the quarter before). 3 opened a new position and 13 sold out. Shares held by institutions: +6%.
| Largest holders | Shares | Value |
|---|---|---|
| BIOS Capital Management, LP | 6,000,000 | $6.90M |
| DAVENPORT & Co LLC | 4,259,511 | $4.90M |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,438,775 | $3.95M |
| BlackRock, Inc. | 1,261,993 | $1.45M |
| Chescapmanager LLC | 997,029 | $1.15M |
| GEODE CAPITAL MANAGEMENT, LLC | 910,006 | $1.05M |
| RENAISSANCE TECHNOLOGIES LLC | 693,288 | $797K |
| Hilton Capital Management, LLC | 548,950 | $631K |
| VANGUARD FIDUCIARY TRUST CO | 508,220 | $584K |
| CM Management, LLC | 450,000 | $518K |
Clinical trial readouts
1 Phase 2 or 3 trials by Cognition Therapeutics Inc with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-05-31 (est.) | CT1812 | Early Alzheimer's Disease | Phase 2 | 540 | Enrollment complete | NCT05531656 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.